Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H25FN8O4 |
Molecular Weight | 532.5263 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC(=O)C2=C(N1)C=C(C)C(CN(CC#C)C3=CC(F)=C(C=C3)C(=O)N[C@@H](CCC4=NN=NN4)C(O)=O)=C2
InChI
InChIKey=IEJSCSAMMLUINT-NRFANRHFSA-N
InChI=1S/C26H25FN8O4/c1-4-9-35(13-16-11-19-22(10-14(16)2)28-15(3)29-25(19)37)17-5-6-18(20(27)12-17)24(36)30-21(26(38)39)7-8-23-31-33-34-32-23/h1,5-6,10-12,21H,7-9,13H2,2-3H3,(H,30,36)(H,38,39)(H,28,29,37)(H,31,32,33,34)/t21-/m0/s1
Molecular Formula | C26H25FN8O4 |
Molecular Weight | 532.5263 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Plevitrexed is a rationally designed, orally bioavailable, nonpolyglutamatable quinazoline antifolate that is a selective inhibitor of thymidylate synthase with potent antineoplastic activity and the ability to overcome antifolate resistance due to decreased folylpolyglutamate synthetase activity. It also features a lower toxicity than polyglutamatable thymidylate synthase inhibitors, presumably due to a lesser cellular retention. Plevitrexed is primarily transported into the cells via reduced folate carrier and selectively binds to the folate-binding site of thymidylate synthase with high affinity. Plevitrexed was assessed and in preclinical studies against a panel of human ovarian cancer cell lines and in several phase II clinical studies for the treatment of various solid cancers including colorectal, gastric, pancreatic and ovarian cancer. The combination of plevitrexed and carboplatin is well tolerated with no significant pharmacokinetic interaction between the two drugs - antitumor activity in platinum-pretreated gynecological malignancy was demonstrated.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. | 1999 Sep 23 |
|
P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells. | 2004 Sep 1 |
|
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. | 2005 Dec 15 |
|
Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I. | 2007 Sep |
|
Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II. | 2008 Feb |
|
Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo. | 2008 Nov |
|
Antifolate inhibitors of thymidylate synthase as anticancer drugs. | 2010 Nov |
|
Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. | 2013 Jul 11 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:11:55 GMT 2025
by
admin
on
Mon Mar 31 18:11:55 GMT 2025
|
Record UNII |
L9P2881C3H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2021
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
||
|
NCI_THESAURUS |
C511
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
L9P2881C3H
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
100000141989
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
DB06163
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
8279
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
C1629
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL126648
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
153537-73-6
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
DTXSID10165351
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
696259
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
135430970
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY | |||
|
SUB107725
Created by
admin on Mon Mar 31 18:11:55 GMT 2025 , Edited by admin on Mon Mar 31 18:11:55 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
ENANTIOMER -> ENANTIOMER |
|
||
|
RACEMATE -> ENANTIOMER |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|